Antibody-based therapies currently hold most promise for first wave of effective and widely applicable COVID-19 treatments and prophylaxis.

Drug-induced liver injury is a leading cause of termination in drug development programmes and removal of drugs from the market.

The latest stories you need to know.

PFS, OS, and ORR were superior in this phase 3 trial.

Convalescent blood plasma has long been used as a therapy against serious diseases, including the Spanish flu, and will likely be used in future pandemics.

'Vaccine nationalism’ will prolong pandemic, warns WHO Director General.

The data suggest that self-reported symptoms substantially overestimate COVID-19 disease relative to serology.

Of the first 40 EU-funded COVID-19 research projects, UK scientists have been partners in projects worth £18 million of the total £50 million investment.

The latest stories you need to know.

NICE said it is unclear how long the treatment benefit would last for carfilzomib with lenalidomide and dexamethasone

Gaining public trust will be key to ensuring successful COVID-19 vaccine uptake.

If a traditional medicine product is found to be safe, efficacious and quality-assured, the WHO will recommend fast-tracked, large-scale local manufacturing.

In this deprived urban population, diagnoses of common conditions decreased substantially between March 2020 and May 2020, suggesting many have undiagnosed issues.

The use of a brief intervention to reduce alcohol use by adults with HIV who are being treated with antiretroviral therapy